 1. Patients with relapsed or refractory PMLBCL who have previously received at least 1 line of treatment. Patients must have completed any prior treatment with radiation, chemotherapy, biologics, immunotherapy andor other investigational agents at least 4 weeks prior to the first dose of Brentuximab vedotin. 